Email Us
Call Us
AUSTIN, Texas, August 28, 2026 – Altogen Labs published a comprehensive framework for xenograft model selection and standardization in JoVE, a practical guide to designing preclinical oncology programs from early efficacy through IND-enabling safety studies. The framework addresses preclinical model selection and the integration of CDX, PDX, orthotopic, humanized, and organoid-derived platforms into oncology research workflows, where each answers a different question at a different stage of development. Three variables govern the choice: tumor source, implantation site, and host immune background. Together they determine engraftment biology, achievable endpoints, study duration, and how far a result can be extended toward the clinic.
CDX models remain the fastest and most cost-effective platform for early in vivo efficacy, reaching readout in 5–7 weeks with large matched cohorts and interpretable dose-response, PK/PD, and tolerability data. Authenticated lines can be genetically manipulated and expanded at scale with comparatively little biological noise, and orthotopic or disseminated variants extend the same lines to tissue tropism and metastatic colonization over 7–12 weeks with imaging-based monitoring. Their limitations define their proper use: clonal drift in culture, absent human stroma, and no immune compartment make CDX a triage and mechanism platform rather than a surrogate for clinical outcome. Much of the historical case against cell line predictivity reflects study design, specifically small panels and absent molecular stratification, rather than intrinsic model failure.
PDX models preserve donor histology, genomic architecture, and intratumoral heterogeneity across early passages, supporting biomarker development, resistance modeling, and co-clinical trial design over 16–32 weeks. Success depends on tissue handling and tumor selection. Material must be transported cold and processed within roughly 24 hours, and engraftment is strongly tumor-dependent: aggressive, poorly differentiated, and treatment-resistant tumors take far more readily than indolent disease. Passage discipline determines data quality. Growth kinetics stabilize only after the earliest passages, formal pharmacology is best reserved for early-passage material, and extensively passaged models carry increasing risk of subclonal outgrowth and transcriptional drift at a rate that is itself tumor-type dependent.
Implantation site is a decision separate from tumor source, and too often made by default. Subcutaneous placement offers caliper monitoring and operational simplicity but diverges from the native organ in matrix composition, vascular architecture, and stromal populations. Orthotopic implantation restores organ-specific microenvironment and supports spontaneous metastasis, at the cost of surgical complexity and imaging-dependent monitoring. Subrenal capsule implantation exploits a highly vascularized site to exceed 90% take in tumors that resist engraftment elsewhere, including non-small cell lung cancer and prostate cancer. Host strain sets the ceiling on what will engraft at all: the progression from athymic nude and CB-17 scid through NSG and NOG represents the systematic removal of T-cell, B-cell, and NK-cell barriers, with NRG preserving DNA-repair competence where irradiation is part of the protocol and the SRG rat supporting models that grow poorly in mice while permitting serial sampling.
Humanized platforms extend both CDX and PDX to immuno-oncology, supporting evaluation of checkpoint inhibitors, bispecific T-cell engagers, and CAR-T products that conventional immunodeficient hosts cannot assess. Configuration determines what those studies can conclude: hu-PBMC models reconstitute T cells rapidly but are bounded by graft-versus-host disease within weeks, hu-CD34 models support longer studies with incomplete myeloid reconstitution, and autologous humanized PDX eliminates MHC mismatch between immune and tumor compartments. Cytokine-transgenic strains including NSG-SGM3, MISTRG6, and NOG-EXL address specific myeloid, NK, and macrophage deficits. Organoid-derived xenografts complete the range, bridging ex vivo screening and in vivo validation in 8–16 weeks with minimal tissue input, which makes them practical where patient material is limiting.
Standardization determines whether any of this transfers between institutions, and four frameworks now apply to xenograft work: PDX-MI, MISHUM, OBSERVE, and the NCI PDXNet recommendations, alongside ARRIVE 2.0. Each governs a different layer — model provenance and passage history, immune reconstitution and GvHD monitoring, welfare endpoints, and tumor growth analysis — and a single study may need to satisfy all four. In practice, passage number, tumor measurement formula, host source, and authentication method are routinely omitted from published work, and inconsistent tumor volume estimation alters treatment effect estimates across studies. Adoption remains uneven across the field, which is why standardized characterization now matters as much to translational value as the choice of platform itself. Altogen Labs applies these standards across its xenograft portfolio, from early CDX efficacy studies through humanized and organoid-derived platforms and IND-enabling work.
The full publication, “Standardized Xenograft Models for Preclinical Cancer Research,” is available at https://www.jove.com/t/71892/standardized-xenograft-models-for-preclinical-cancer-research. Timelines reflect standard operating procedures implemented at Altogen Labs and are specific to tumor type, host strain, and study design.
About Altogen Labs
Altogen Labs is a preclinical contract research organization headquartered in Austin, Texas, providing xenograft efficacy studies, pharmacology and PK/PD characterization, toxicology, and IND-enabling studies for oncology drug development. The company maintains CDX, PDX, orthotopic, humanized, and organoid-derived models across major tumor types.
Contact
Altogen Labs | 11200 Menchaca Rd, Austin TX 78748